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Abstract
Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However,
investigations of clinically useful tumor biomarkers are time-consuming, costly, and limited by patient and tumor
heterogeneity. In addition, assessment of biomarkers as indicators of therapy response is confounded by the concomitant
use of multiple therapeutic interventions. Herein we report our use of a clinically relevant orthotopic animal model of
malignant pleural mesothelioma for investigating tumor biomarkers. Utilizing multi-modality imaging with correlative
histopathology, we demonstrate the utility and accuracy of the mouse model in investigating tumor biomarkers – serum
soluble mesothelin-related peptide (SMRP) and osteopontin (OPN). This model revealed percentage change in SMRP level to
be an accurate biomarker of tumor progression and therapeutic response – a finding consistent with recent clinical studies.
This in vivo platform demonstrates the advantages of a validated mouse model for the timely and cost-effective acceleration
of human biomarker translational research.
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Introduction
Serum or plasma tumor biomarkers provide reliable, easily
measurable, and noninvasive indicators of cancer detection,
disease progression, and therapy response. However, clinical
investigations of biomarkers are constrained by patient heteroge-
neity and selection bias, particularly in the setting of rare
malignancies such as malignant pleural mesothelioma (MPM)
[1,2]. MPM is an aggressive cancer of the pleural linings of the
lungs and chest wall with an annual incidence of fewer than 3,000
cases in the US [3]. Clinical investigation of MPM biomarkers is
hindered by disease rarity as well as a dismal median survival of 9–
17 months even with the best available therapy [4,5]. Despite over
450 publications investigating MPM biomarkers, no candidate
MPM biomarker has become a standard of care.
Currently, the only biologic metric of response to MPM therapy
is the use of radiological endpoints. Multiple serial radiographic
measurements required to monitor therapy response are not only
costly but also suffer from inter-observer variations due to the
unique growth pattern of MPM as a pleural rind instead of discrete
tumor nodule [6]. In addition, the standard Response Evaluation
Criteria in Solid Tumors (RECIST) used to assess therapy
response in solid tumors is inadequate for MPM because of the
limitation of one-dimensional measurement for change in pleural
tumor burden [7]. Although FDG-PET (fludeoxyglucose positron
emission tomography) scans have been shown to correlate
with therapy response [8,9], this technique possesses shortcomings
in interpretations including false-positive uptake in inflamed
tissues. This highlights the need for biomarkers that can be
utilized to provide a quantitative measure of disease progression
and therapy response. Furthermore, the use of biomarkers offers a
potential investigational tool to understand tumor biology and the
efficacy of novel experimental therapies in pre-clinical animal
models.
To investigate the utility of MPM biomarkers that are currently
in clinical investigations, we utilized an orthotopic MPM mouse
model. Our initial studies showed that commonly used MPM flank
tumor models are unreliable for biomarker investigations due to
unpredictable variations in serum levels as tumors grow larger and
central necrosis occurs in late stages of disease. Likewise, in
intraperitoneal models, accurate non-invasive quantification of
tumor burden is limited due to the distribution of the tumor. In the
current study, we developed a well-characterized orthotopic
pleural animal model that closely resembles human MPM. We
then utilized this model to investigate two candidate MPM
biomarkers - soluble mesothelin-related peptide (SMRP) and
osteopontin (OPN). In addition to allowing the investigation of
candidate biomarkers for a rare malignancy, our study demon-
strates the utility of mouse models to determine biomarker
response to therapy.
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Materials and Methods
Ethics Statement
All procedures were performed under approved Institutional
Animal Care and Use Committee (IACUC) protocols (#08-01-001).
Generation of mesothelin and GFP-Luciferase MPM cells
The human MPM cell line, MSTO-211H (American Type
Culture Collection), was maintained RPMI-supplemented with 10%
fetal bovine serum, 100 units/mL penicillin, and 100 ug/mL
streptomycin in a 5% CO2 humidified incubator at 37uC. Green
fluorescent protein (GFP)-Firefly luciferase fusion and human
mesothelin (MSLN) genes were cloned into SFG retroviral vectors,
which were then transfected into H29 packaging cell line using
calcium phosphate mediated transfection protocol. MSTO-211H
cells were plated in 24-well plates 24 hours prior to retroviral
transduction. Media containing filtered virus was added to cells
permeablized using 8 ug/mL polybrene (Sigma-Aldrich, MO). Cells
were reinfected with freshly collected virus 24 hours later. The
human MSLN variant 1 was isolated from the human MSLN-
expressing ovarian cancer cell line OVCAR using TRIzol Reagent.
RT-PCR synthesis of full length cDNA of human MSLN was
performed using SuperScriptTM III One-Step RT-PCR System with
PlatinumH Taq High Fidelity Kit. The 59 primer is GAT CTA CAC
AGA CCA TGG CCT TGC CAA CGG, including a Nco I site,
and the 39 primer is GCG CAG ATC TTA CGT ATC AGG CCA
GGG TGG AGG CTA G, including a Bgl II site and a Sna BI site.
Plasmid DNAwas isolated, subcloned into the SFG retroviral vector,
confirmed by sequencing, and used to stably transduce MSLN.
Flow Cytometry
Flow activated cell sorting (FACS) was performed using
FACSAria (BD Biosciences). Human mesothelin cell-surface
expression was detected using a phycoerythrin-conjugated or
allophycocyanin-conjugated anti-human mesothelin rat IgG2A
(R&D systems, MN). Flow cytometry for GFP and mesothelin
expression was performed on LSRII cytometer (BD Biosciences)
and analyzed using FlowJo (Tree Star) software.
Generation of orthotopic MPM mouse model
Female SCID/beige and male athymic nude mice (6–10 weeks
of age, Taconic Farms, NY) were used. Mice anesthetized with
inhaled isoflurane and oxygen underwent direct intrapleural
injection of tumor cells in 200 uL serum-free media via a right
thoracic incision. Following inoculation, tumor take and progression
occurred in.95% of mice. Mice were sacrificed when moribund as
per IACUC guidelines. The details of our intrapleural xenografting
technique have been previously described [10,11,12].
Immunofluorescence
Immunofluorescence staining for angio- and lymphangiogenesis
was performed using CD34 rat monoclonal (eBioscience) and
LYVE-1 goat polyclonal (R&D Systems) antibodies, respectively.
Immunofluorescencent detection was performed with Streptavi-
din-HRP D (Ventana Medical Systems), followed by incubation
with Tyramide-Alexa Fluor 488 (Invitrogen) or Tyramide Alexa
Fluor 568 (Invitrogen) for CD34 and LYVE-1, respectively. The
protocols were established and experiments performed at the
Molecular Cytology Core Facility, MSKCC, using Discovery XT
automatic processor from Ventana Medical Systems.
Quantitative bioluminescence imaging
In vitro bioluminescence imaging (BLI) standardization was
performed using GFP-Firefly luciferase expressing MSTO-211H
cells with and without MSLN expression. Cells were plated in 96-
well tissue culture plates in serial dilution from 1.66106 to 2.56104
cells/100 mL/well. Twenty minutes after the addition of 100 mL
D-Luciferin to each well (15 mg/mL; Caliper Lifesciences, MA),
plates were imaged using the Xenogen IVIS 100 Imaging System
(Caliper Lifesciences). BLI data were analyzed using Living Image
2.60 software. Cell number versus total BLI flux (photon/s) was
evaluated by Pearson’s correlation.
In vivo BLI in tumor-bearing mice was performed using a single
intraperitoneal dose of 150 mg/kg D-Luciferin. Mice were imaged
with the Xenogen IVIS 100 Imaging System 20 minutes following
D-Luciferin injection and images acquired for 5–30 seconds
depending on signal strength. BLI data were analyzed using
Living Image 2.60 software; BLI signal from regions of interest
(ROI) were reported as total flux (photons/s).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed on mice
anesthetized with 1% isoflurane in 20% Oxygen and imaged in a
Bruker 4.7T USR scanner (Bruker Biospin Inc., Ettlingen,
Germany) equipped with a 400 mT/m gradient coil and a
32 mm ID custom build birdcage resonator. Thoracic axial MRI
images were acquired using a RARE fast spin-echo sequence with
a repetition time (TR) of 1.7 s, echo time (TE) 40 ms and 12
averages. The acquisition was triggered by animal respiration to
reduce respiration induced motion artifacts. The slice thickness
was 0.7 mm and the in-plane image resolution was 1176156 mm.
Tumor volumes (mm3) were measured by tracing tumor
boundaries in each slice using Bruker ParaVision Xtip software
(Bruker Biospin Inc., Ettlingen, Germany) and then calculated
from the areas of tumor regions in each slice.
Serum SMRP and OPN assay
Blood was collected in K2EDTA tubes, immediately centrifuged
to separate serum, and stored at 220uC until assayed. Soluble
mesothelin-related peptide (SMRP) was measured using an ELISA
microplate sandwich assay (MesomarkH Fujirebio Diagnostics,
Inc). The detection limit of this assay was 0.3 nM. Serum
osteopontin (OPN) was measured using QuantikineH OPN
immunoassay. The assay, performed per manufacturer’s instruc-
tions, is a solid-phase ELISA employing a sandwich immunoassay
to quantitate human OPN. Samples were measured in duplicate
with standard controls.
Chemo- and radiation therapy
Biomarker performance in evaluating therapy response was
assessed in Nude Athymic male mice, in which orthotopic pleural
tumors, expressing both GFP-Luciferase and human mesothelin,
were established as described above. Tumors progressed for 22
days following inoculation at which time equivalent tumor burden
was confirmed by BLI signal and mice were divided into
experimental groups. Mice received either: (a) cisplatin (4 mg/kg
IP weekly), (b) isolated thoracic radiation (20 Gy total in 5
fractions), (c) combination chemoradiation, or (d) no treatment.
Isolated thoracic radiation was provided using the XRAD-320
(Precision X-ray, CT) 250 kVp, 12 mA, 0.25 mm Cu filtration in
conjunction with lead barrier protection of the mouse peritoneal
cavity. Treatment was provided for two weeks and the mice were
monitored serially with BLI and serum SMRP assessment.
Differences in BLI signal and SMRP levels between treatment
groups were assessed by Kruskal-Wallis test using area under the
curve analysis and Student’s t-test, respectively. Predictive value of
SMRP for survival following treatment was evaluated using
An In Vivo Platform for Tumor Biomarker Assessment
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26722
analysis of maximum likelihood estimates and reported as hazard
ratios.
Results
Quantitative bioimaging in a clinically relevant mouse
model
To evaluate biomarkers for MPM, we utilized an intrapleural
mouse model. This model recapitulates the human tumor
microenvironment grossly and histopathologically (Fig. 1A). In
addition, the extensive vascularization of the MPM tumors in our
model (Fig. 1B) facilitates detection of serum biomarker. This
clinically relevant model provided an appropriate platform to
investigate biomarkers for clinical translation. To non-invasively
monitor tumor progression, we validated bioluminescent imaging
(BLI) as an accurate, quantitative modality to assess tumor burden.
We confirmed a linear correlation between number of mesothe-
lioma cells (transduced to express firefly-luciferase) and BLI
photon counts in vitro (Pearson r = 0.999, p,0.0001) and demon-
strated that BLI can detect as few as 16103 tumor cells in the
pleural space of mice (data not shown). We next demonstrated a
strong correlation between bioluminescent flux and pleural tumor
volume as determined by magnetic resonance imaging (MRI), the
gold standard for tumor volume assessment [13] (r = 0.86,
p,0.0001, adjusted for within mouse clustering; Fig. 1C and D).
Accurate, quantitative BLI is possible in this model because tumor
grows along the chest wall as a thickening of the pleural rind
minimizing tumor depth and BLI signal attenuation (Fig. 1A).
These experiments established that BLI in the orthotopic pleural
model provides an accurate, non-invasive, serial, and quantitative
evaluation of tumor burden.
In vivo biomarker assessment of tumor progression
We next sought to evaluate the candidate mesothelioma tumor
biomarker, SMRP. SMRP is a cleavage product of the cell-surface
protein mesothelin, overexpressed by epithelioid MPM (the most
Figure 1. Orthotopic mouse model of MPM permits noninvasive, quantitative bioimaging of tumor progression. A, The mouse model
of MPM recapitulates human disease and H&E staining of mouse chest wall (arrowhead at rib) with MPM demonstrates the pleural growth pattern of
tumor (arrows) similar to human disease as an increased thickening of the pleural rind permitting quantitative BLI. B, Immunofluorescence staining
demonstrates extensive angiogenesis (CD34 – green) in the advanced orthotopic pleural tumor permitting SMRP detection in serum. C–D, Serial BLI
in pleural xenograft mice accurately reflects tumor burden as correlated with gold-standard assessment by serial volumetric MRI in the live mouse
(r = 0.86, p,0.0001*). * Sample size corresponds to total number of measurements over time in a group of 14 mice; p-values are adjusted for within
mouse clustering.
doi:10.1371/journal.pone.0026722.g001
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common MPM subtype), and has shown promise as a tumor
biomarker [3,14,15,16]. We first confirmed sustained mesothelin
expression in the orthotopic MPM model by immunohistochem-
istry and flow cytometry even at advanced stages of disease (data
not shown). We observed that SMRP in the pleural MPM model
correlated with tumor burden and progression as confirmed by
MRI tumor volume and BLI signal (Fig. 2A–C). We simulta-
neously evaluated serum OPN, another candidate serum MPM
biomarker. Using the aforementioned quantitative imaging
parameters, serum OPN levels neither correlated with tumor
burden (Fig. 2D) nor SMRP level. Based on these observations, we
only evaluated SMRP in subsequent experiments.
In vivo biomarker assessment of therapy response
To examine the importance of a serum biomarker in predicting
therapy response in MPM, we evaluated serum SMRP levels
following multimodality treatment of mice with orthotopic pleural
tumors. Immunodeficient nude athymic mice were engrafted with
human MPM tumor cells intrapleurally and then treated for two
weeks with multimodality therapy (Fig. 3A). Mice were monitored
using serial serum SMRP, BLI, and followed for survival. We
noted a significant decrease in serum SMRP level in the treatment
groups compared to controls. Although SMRP increased during
chemoradiation treatment cycles (days 0–11), the rate of increase
was significantly decreased (slope of 0.04 versus 0.21 for controls,
Wilcoxon test, p = 0.01; Fig. 3B). Decreased serum SMRP
correlated with slowed tumor progression as reflected in BLI
signal following treatment compared to control mice (data not
shown). In addition, elevated serum SMRP was associated with an
increased risk of death (hazard ratio = 4.5, 95% CI 1.53–13.1).
Using this mouse model we demonstrated that the percentage
change in SMRP levels correlates with survival and response to
therapy (defined as ,2-fold increase in BLI signal over the
treatment period). Following treatment, the percent increase in
SMRP level was significantly lower in mice that responded to
therapy compared to non-responders (10-fold vs. 17-fold increase,
p = 0.009, Fig. 3C). Mice with a lower percent increase in SMRP
(less than the group median) demonstrated improved survival
compared to mice with a higher percent SMRP increase
(p,0.001, Fig. 3D).
Biomarker evaluation of novel therapies
Having evaluated the use of SMRP in the mouse model to
detect therapeutic response following standard therapies, we next
assessed the utility of the model in evaluating the efficacy of an
emerging targeted therapy. Our laboratory is developing a
targeted T-cell immunotherapy for MPM based upon our
experience with genetically modified targeted human T cells
[17]. Treatment response following MPM-targeted T-cell therapy
versus control (unpublished observations), as defined as ,2-fold
increase in BLI signal over the treatment period, was associated
with percentage change in SMRP (0.62-fold decrease vs.11-fold
increase, p= 0.002, Fig. 4A). This noninvasive biomarker
assessment has guided the dosing schedule in our ongoing
Figure 2. SMRP correlates with tumor volume and progression. A–C, SMRP increases with tumor progression and correlates with BLI signal
(r = 0.92, p,0.0001) and tumor volume by MRI (r = 0.87, p,0.0001). D, The mouse model demonstrates that SMRP, but not OPN, correlates with tumor
progression in MPM with less variability, as also observed in patients.
doi:10.1371/journal.pone.0026722.g002
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Figure 3. SMRP is a biomarker of therapy response. A, Nude athymic mice xenografted with human MPM tumors were treated with either:
cisplatin (4 mg/kg IP weekly), isolated thoracic radiation (20Gy total in 5 fractions), combination chemoradiation, or no treatment. Differential response
to therapy was monitored by BLI signal and serum SMRP. B, Serum SMRP was significantly decreased in treatment groups compared to controls as
reflected by a lower increase in SMRP over the treatment period (Wilcoxon test, p = 0.01). C, Treatment response following therapy, defined as less than a
2-fold increase in BLI signal over the treatment period, was associated with lower percent increase in SMRP as shown by the waterfall plot (p = 0.009).
Note that all treatment groups had increasing tumor despite therapy, reflecting the limited effectiveness of standard therapies against MPM. Therefore,
‘‘response’’ versus ‘‘no response’’ is relative to the median percentage increase in SMRP (a 12-fold increase) for the entire cohort. D, Additionally, mice
with low percent SMRP increase (less than the group median) demonstrated improved survival following therapy (p,0.001).
doi:10.1371/journal.pone.0026722.g003
Figure 4. Utility of mouse model in evaluating biomarker response to therapy. A, Treatment response following T-cell immunotherapy,
MPM-targeted versus control, defined as less than a 2-fold increase in BLI signal over the treatment period, was associated with percentage change in
SMRP as illustrated by the waterfall plot (0.62-fold decrease vs. 11-fold increase, p = 0.002). B, SMRP sensitively detected early tumor relapse (arrow)
following a single low-dose targeted therapy as indicated by a concomitant rise in BLI signal and serum SMRP.
doi:10.1371/journal.pone.0026722.g004
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immunotherapy experiments. Serum SMRP was a sensitive
indicator of tumor progression following a response to an initial
treatment with targeted T cells (Fig. 4B). These experiments
demonstrate that serum SMRP is a sensitive, noninvasive marker
of tumor response to therapy and relapse.
Discussion
In summary, we have described an in vivo platform to investigate
serum tumor biomarkers by combining quantitative bioimaging
with an orthotopic mouse model. This report demonstrates that an
orthotopic MPM mouse model provides a convenient and
powerful platform to systematically evaluate biomarkers for
monitoring tumor burden, disease progression, and therapeutic
response – a process that is hindered in heterogeneous patient
populations, particularly with rare diseases such as MPM. We
have shown that this mouse model allows for accurate quantitative
BLI and MRI and that serum SMRP, but not OPN, provides a
sensitive biomarker of disease in MPM. The results of this study
parallel the recently published clinical observations for SMRP and
OPN in patients [16,18], which demonstrate superiority of serum
SMRP and limited utility of serum OPN as biomarker in MPM. It
is notable that these preliminary clinical data [18] were obtained
from a sample of 41 patients, taking 21 months to accrue, in
contrast to our pre-clinical study requiring less than six months. In
this mouse model, SMRP provides an early indication of
therapeutic response during ongoing chemotherapy and radiation
treatment. These results demonstrate the utility of biomarker
assessment to detect therapeutic response at a cellular level, in
contrast to standard imaging modalities, which detect macroscopic
responses occurring at a later stage. This is particularly important
for MPM, in which assessment of disease progression or therapy
response is currently performed by serial CT [6] or PET scans
[8,9].
With the rise of ‘personalized medicine’, the value of biomarkers
has become even more important in monitoring the efficacy of
targeted therapies. We have shown that investigational therapies
can be evaluated by correlating response to biomarkers in the
mouse model providing a quantifiable parameter of response in
addition to survival and helping to guide novel therapy treatment
schedules. In developing such preclinical models, our study
highlights the importance of utilizing orthotopic tumor models
that recapitulate the tumor microenvironment and the use of
validated correlative modalities to assess tumor progression, such
as quantitative bioimaging. Furthermore, this study demonstrates
the utility of orthotopic mouse models in preclinical studies of
tumor biomarkers, biology, and therapy evaluation. In conclusion,
we have developed an in vivo platform, which will allow for
preclinical investigations of candidate biomarkers and can
accelerate the design of biomarker clinical trials and ultimately
translation to clinical application.
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